Citigroup Reiterates Positive Rating on BioPharma
Steady: 0 in the last 7 days
Updated oct 15
The latest in this situation
How it started
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citigroup reiterated a positive rating on shares of BioPharma. This rating was issued in a research report on Tuesday, September 22nd, according to one report. The company is publicly traded on the Nasdaq stock exchange.
From themarketsdaily.com
Why it matters
Investment ratings from Citigroup influence market perception of BioPharma. The stock currently has a consensus rating of “Hold” and an average target price of $14.50.
From themarketsdaily.com
Who's involved
How it developed
Newest first. Tap a step to see who reported it.- Citigroup reiterated a market perform rating for Inhibrx Biosciences.Sub-event
Citigroup reiterated a positive rating on BioPharma.1 source
Keep exploring
The entities involved
-
Citigroup
American investment bank and financial services corporation
-
BioPharma
company in Jílové u Prahy, Czech Republic
Nothing else this week.
Related events
- Citigroup restated a buy rating on shares of Intensity Therapeutics.
- Citigroup reiterated a market outperform rating for Alphabet Inc.
- Bank of America updated its price objective and rating, while Citigroup reissued a neutral rating on Biogen shares.
- Citigroup reissued a neutral rating on Man Group, a company headquartered in London.
- Citigroup reissued a market outperform rating for Applied Digital Corporation on October 15, 2026.